Concord Biotech Ltd. (IN:CONCORDBIO)
:CONCORDBIO
Want to see IN:CONCORDBIO full AI Analyst Report?
Total Valuation
Concord Biotech Ltd. has a market cap or net worth of ₹140.74B. The enterprise value is ₹109.86B.
Market Cap₹140.74B
Enterprise Value₹109.86B
Share Statistics
Concord Biotech Ltd. has 104,616,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding104,616,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Concord Biotech Ltd.’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 10.66%.
Return on Equity (ROE)0.13
Return on Assets (ROA)0.12
Return on Invested Capital (ROIC)10.66%
Return on Capital Employed (ROCE)0.14
Revenue Per Employee7.66M
Profits Per Employee1.89M
Employee Count1,377
Asset Turnover0.47
Inventory Turnover1.88
Valuation Ratios
The current PE Ratio of Concord Biotech Ltd. is 54.6. Concord Biotech Ltd.’s PEG ratio is -1.36.
PE Ratio54.6
PS Ratio10.16
PB Ratio5.32
Price to Fair Value5.32
Price to FCF61.58
Price to Operating Cash Flow94.04
PEG Ratio-1.36
Income Statement
In the last 12 months, Concord Biotech Ltd. had revenue of 10.55B and earned 2.61B in profits. Earnings per share was 24.78.
Revenue10.55B
Gross Profit4.42B
Operating Income2.93B
Pretax Income3.45B
Net Income2.61B
EBITDA4.19B
Earnings Per Share (EPS)24.78
Cash Flow
In the last 12 months, operating cash flow was 1.51B and capital expenditures -534.99M, giving a free cash flow of 975.85M billion.
Operating Cash Flow1.51B
Free Cash Flow975.85M
Free Cash Flow per Share9.33
Dividends & Yields
Concord Biotech Ltd. pays an annual dividend of ₹7.55, resulting in a dividend yield of 0.8%
Dividend Per Share₹7.55
Dividend Yield0.8%
Payout Ratio34.63%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.14
52-Week Price Change-34.95%
50-Day Moving Average1.13K
200-Day Moving Average1.33K
Relative Strength Index (RSI)70.57
Average Volume (3m)12.81K
Important Dates
Concord Biotech Ltd. upcoming earnings date is Aug 7, 2026, Before Open (Confirmed).
Last Earnings DateMay 29, 2026
Next Earnings DateAug 7, 2026
Ex-Dividend Date―
Financial Position
Concord Biotech Ltd. as a current ratio of 7.39, with Debt / Equity ratio of 0.11%
Current Ratio7.39
Quick Ratio5.46
Debt to Market Cap0.00
Net Debt to EBITDA-0.03
Interest Coverage Ratio1.03K
Taxes
In the past 12 months, Concord Biotech Ltd. has paid 854.18M in taxes.
Income Tax854.18M
Effective Tax Rate0.25
Enterprise Valuation
Concord Biotech Ltd. EV to EBITDA ratio is 25.54, with an EV/FCF ratio of 61.51.
EV to Sales10.15
EV to EBITDA25.54
EV to Free Cash Flow61.51
EV to Operating Cash Flow39.78
Balance Sheet
Concord Biotech Ltd. has ₹3.81B in cash and marketable securities with ₹16.07M in debt, giving a net cash position of ₹3.80B billion.
Cash & Marketable Securities₹3.81B
Total Debt₹16.07M
Net Cash₹3.80B
Net Cash Per Share₹36.30
Tangible Book Value Per Share₹191.22
Margins
Gross margin is 55.81%, with operating margin of 27.77%, and net profit margin of 24.73%.
Gross Margin55.81%
Operating Margin27.77%
Pretax Margin32.67%
Net Profit Margin24.73%
EBITDA Margin39.76%
EBIT Margin32.70%
Analyst Forecast
The average price target for Concord Biotech Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-12.10%
EPS Growth Forecast-29.87%